Archives
-
Eudragit S 100-Coated LNPs for Oral RNA Delivery
2026-09-12
Haque, Shrestha, and Mattheolabakis developed a pH-responsive Eudragit S 100 coating for lipid nanoparticles containing RNA. The coating protected payloads under simulated gastric conditions while preserving transfection after exposure to simulated gastrointestinal fluids, supporting further investigation of non-injectable RNA delivery.
-
Machine Learning Predicts LNPs for mRNA Vaccines
2026-09-11
Wang and colleagues developed a LightGBM model from 325 mRNA vaccine lipid nanoparticle formulations and reported an R² above 0.87 for predicting IgG responses. The study combined computational prediction with mouse validation and molecular dynamics, showing how formulation screening may be accelerated while still requiring experimental confirmation.
-
LG 101506: RXR Modulator Workflow Guide
2026-09-11
LG 101506 enables controlled perturbation of RXR biology in cancer and metabolic models without conflating pathway modulation with direct PD-L1 targeting. This practical guide translates a TNBC immune-checkpoint study into dose design, orthogonal readouts, troubleshooting, and mechanism-focused assay workflows.
-
5-Aminolevulinic Acid HCl in Heme Research
2026-09-10
Explore how 5-Aminolevulinic acid HCl can function as a pathway probe rather than merely a heme precursor. This article translates new Salmonella–macrophage findings into practical assay-design guidance while distinguishing bacterial haem biology from mammalian photodynamic applications.
-
Reparixin for IL-8–CXCR1/2 Mechanism Studies
2026-09-10
Reparixin provides a receptor-level way to test whether IL-8–CXCR1/2 signaling connects bacterial extracellular vesicles with tumor-cell growth and neutrophil recruitment. This workflow combines EV comparison, pharmacological blockade, chemotaxis testing, and tissue-injury models while separating evidence-backed parameters from assay-development recommendations.
-
KPT-330 (Selinexor): CRM1 Inhibition in Cancer Research
2026-09-09
KPT-330 (Selinexor) is an orally bioavailable selective CRM1/XPO1 inhibitor that blocks nuclear export and supports preclinical apoptosis and cell-cycle studies. In basal-like triple-negative breast cancer models, KPT-330-containing combinations produced synergistic activity in vitro and improved tumor control in patient-derived xenografts.
-
Palonosetron: Pharmacology, PK, and CINV Evidence
2026-09-09
The 2010 reference study integrated receptor pharmacology, animal emesis models, pharmacokinetics, and randomized clinical evidence to define palonosetron as a highly selective 5-HT3 receptor antagonist with unusually sustained activity. Its most meaningful clinical finding was noninferiority to granisetron for acute symptoms and superiority for delayed chemotherapy-induced nausea and vomiting.
-
L-Phenylephrine: Designing Sex-Aware α1A Assays
2026-09-08
L-Phenylephrine is an adrenergic α1A receptor agonist that can refine cardiovascular assay design beyond simple vasoconstriction models. This guide translates sex-dependent angiotensin II hypertension findings into practical, mechanistically informed workflows for receptor, baroreflex, cardiomyocyte, and neural research.
-
ERCC1 Deficiency, p53, and Platinum Response
2026-09-08
Heyza and colleagues show that p53 status substantially modifies the response of ERCC1-deficient lung cancer cells to cisplatin and other interstrand crosslink stress. Their CRISPR-based models and patient-data analyses indicate that ERCC1 expression alone is an incomplete platinum-response biomarker because alternative repair and survival programs can preserve viability when p53 is defective.
-
2-Thio-dCTP and the Road to Mitotic Mechanism
2026-09-07
This thought-leadership article connects 2-Thio-dCTP chemistry with emerging insights into SCP4-mediated H3T3 dephosphorylation and chromosome stability. It provides a translational framework for validating modified-nucleotide incorporation, separating established findings from exploratory chromatin applications, and selecting fit-for-purpose DNA synthesis workflows.
-
Cx43/NF-κB Signaling in AngII Macrophage Polarization
2026-09-07
The reference study identifies a connexin 43–NF-κB pathway through which angiotensin II promotes pro-inflammatory M1 polarization in RAW264.7 macrophages. Its combined use of molecular, cytokine, phenotypic, and pharmacological readouts provides a useful framework for testing how Cx43-directed interventions influence inflammatory macrophage biology.
-
ddhCTP: Reading Antiviral Assay Signals
2026-09-05
ddhCTP is more than a chain-terminating antiviral nucleotide analog. This guide shows how to separate direct RNA polymerase inhibition from broader viperin effects and design assays that support stronger conclusions in antiviral drug development.
-
ddhCTP: Mechanism and Antiviral Research Use
2026-09-04
ddhCTP, also called 3ʹ-deoxy-3′,4′-didehydro-CTP, is a viperin-derived antiviral nucleotide analog that can terminate RNA synthesis by selected viral RNA-dependent RNA polymerases. Its defined molecular identity, water solubility, cold-storage requirement, and reported flavivirus activity make it useful for mechanistic assays and antiviral drug development.
-
ddhCTP: Mechanism and Antiviral Research Use
2026-09-04
ddhCTP, also called 3ʹ-deoxy-3′,4′-didehydro-CTP, is a viperin-generated nucleotide analog that can terminate RNA synthesis by selected viral RNA-dependent RNA polymerases. Its defined mechanism and reported activity against flaviviruses make it a useful RNA virus replication inhibitor for antiviral research, while coronavirus data show that activity is virus-specific.
-
ZCL278: From Cdc42 Activity to Causal Assays
2026-09-03
ZCL278 is a selective Cdc42 inhibitor for connecting GTPase activity with cell behavior and pathway-specific phenotypes. This article presents an assay-centered framework that distinguishes direct target engagement from downstream effects, using kidney fibrosis research as a translational case study.